CCR Antagonist

CCR Antagonists (31):

Cat. No.	Product Name	Effect	Purity

HY-112874

BMS-681	Antagonist
BMS-681 is an orthosteric antagonist of CC chemokine receptor 2 (CCR2). BMS-681 restricts the movement of the extracellular end of TM6 by stabilizing TM7. TM7 and TM6 are the main components of the orthosteric binding site. BMS-681 can be used to study inflammatory neurodegenerative diseases and cancer.

HY-116835

BI-6901	Antagonist	99.94%
BI 6901 is a potent, selective CCR10 antagonist (pIC₅₀=9.0). BI 6901 shows high selectivity over other GPCRs, including a number of other chemokine receptors. BI 6901 is efficacious in the murine DNFB model of contact hypersensitivity and can be used for inflammation research.

HY-P99697

Leronlimab	Antagonist	98.91%
Leronlimab (PRO 140) is a humanized IgG4 anti-CCR5 monoclonal antibody. Leronlimab inhibits CCR5-mediated HIV-1 viral and lung metastasis in mouse tumor models. Leronlimab can be used for the research of HIV nonalcoholic steatohepatitis (NASH) and cancer.

HY-156460

CMKLR1 antagonist 1	Antagonist	99.44%
CMKLR1 antagonist 1 (compound S-26d) is a potent and orally active chemokine-like receptor 1 (CMKLR1) antagonist, with a pIC₅₀ value of 7.44 in hCMKLR1-transfected CHO cells. CMKLR1 antagonist 1 can be used for psoriasis and metabolic diseases research.

HY-123763

MLN3126	Antagonist	98.64%
MLN3126 is an orally active and potent CCR9 antagonist. MLN3126 inhibits CCL25-induced calcium mobilization and chemotaxis of mouse primary thymocytes, wiht an IC₅₀ value of 6.3 nM for calcium influx.

HY-153670

IPG7236	Antagonist	98.54%
IPG7236 is a selective CCR8 antagonist. IPG7236 exhibits significant tumor suppression in a mouse xenograft model of human breast cancer. IPG7236 can be used in cancer research.

HY-109511

AZD-1678	Antagonist	98.12%
AZD-1678 is a potent CCR4 receptor antagonist, with a pIC₅₀ of 8.6.

HY-112792A

(1S)-CCR2 antagonist 1	Antagonist	98.03%
(1S)-CCR2 antagonist 1 is a left-handed chiral body of CCR2 antagonist 1 (HY-112792). CCR2 antagonist 1 is a high-affinity and long-residence-time CCR2 antagonist, with a K_i of 2.4 nM.

HY-162495

IDOR-1117-2520	Antagonist	99.94%
IDOR-1117-2520 is a potent and selective antagonist of CCR6. IDOR-1117-2520 antagonizes the CCL20-mediated calcium flow (IC₅₀ = 63 nM) and inhibits β-arrestin recruitment to human CCR6 (IC₅₀ = 30 nM) in cells expressing recombinant human CCR6. IDOR-1117-2520 can be used for research of autoimmune diseases.

HY-125836

CCR4 antagonist 2	Antagonist
CCR4 antagonist 2 (Compound 31) is a novel potent, orally bioavailable small molecule antagonists of CC chemokine receptor 4 (CCR4) that inhibits T_reg trafficking into the Tumor Microenvironment without suppressing the number of Treg in healthy tissues. CCR4 antagonist 2 (Compound 31) exhibits IC₅₀ values of Ca²⁺flux and (chemotaxis) CTX are 40 nM and 70 nM, respectively.

HY-114193

CCR1 antagonist 6	Antagonist
CCR1 antagonist 6 (compound 16q) is a chemokine receptor 1 (CCR1) antagonist, with an IC₅₀ of 3 nM.

HY-114194

CCR1 antagonist 7	Antagonist
CCR1 antagonist 7 (compound 16r) is a chemokine receptor 1 (CCR1) antagonist, with an IC₅₀ of 4 nM.

HY-115874

BMS-753426	Antagonist
BMS-753426 is a potent and orally bioavailable antagonist of CCR2.

HY-114097A

CCR1 antagonist 11 hydrochloride	Antagonist
CCR1 antagonist 11 hydrochloride (A1B1) is an orally active CCR1 antagonist with the IC₅₀ values of 0.03 μM, 0.58 μM and 0.32 μM for hCCR1, mCCR1 and rCCR1, respectively. CCR1 antagonist 11 hydrochloride can be used in the study of rheumatoid arthritis and other related inflammatory diseases.

HY-13004R

Maraviroc (Standard)	Antagonist
Maraviroc (Standard) is the analytical standard of Maraviroc. This product is intended for research and analytical applications. Maraviroc (UK-427857) is a selective CCR5 antagonist with activity against human HIV.

HY-B0155

Vicriviroc	Antagonist
Vicriviroc (SCH 417690) is an orally active CCR5 antagonist with the IC₅₀ of 10 nM, and also inhibts MIP-1α and intracellular calcium release induced by the ligand RANTES (10 nM) with the IC₅₀ values of 0.91 nM and 16 nM,,respectively. Vicriviroc can inhibits human immunodeficiency virus type 1 (HIV-1) infection, and can also used for study of cancer.

HY-14388

PF-232798	Antagonist
PF-232798 is an orally active CCR5 antagonist with anti-HIV effects.

HY-13245B

(Rac)-PF-4136309	Antagonist	≥98.0%
(Rac)-PF-4136309 is an isoform of PF-4136309 (HY-13245), which is a potent, selective, and orally bioavailable CCR2 antagonist, with IC₅₀s of 5.2 nM, 17 nM and 13 nM for human, mouse and rat CCR2.

HY-B0155B

Vicriviroc malate	Antagonist
Vicriviroc (SCH 417690) malate is an orally active CCR5 antagonist with the IC₅₀ of 10 nM, and also inhibts MIP-1α and intracellular calcium release induced by the ligand RANTES (10 nM) with the IC₅₀ values of 0.91 nM and 16 nM,,respectively. Vicriviroc malate can inhibits human immunodeficiency virus type 1 (HIV-1) infection, and can also used for study of cancer.

HY-148232

BAY-3153	Antagonist
BAY-3153 is a selective CCR1 (C-C motif chemokine receptor 1) antagonist (human IC₅₀=3 nM; rat IC₅₀=11 nM; mice IC₅₀=81 nM).

Name
Email *

	Sorry, but the email address you supplied was invalid.